Actavis FTC Accord Clears Way for Warner Chilcott Deal

Actavis Inc. agreed to sell assets covering four generic drugs in a settlement with U.S. regulators that clears the way for its $8.5 billion acquisition of Warner Chilcott Plc.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.